Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hagan Introduces Long-Anticipated TREAT Act, Sans Progressive, Exceptional Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Bill looks to expand accelerated approval rather than create new approval pathways, and also would reform conflict of interest rules for FDA advisory committees.

You may also be interested in...



Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed

At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.

FDA Conflict Of Interest Policy May Be Biggest Conflict Of PDUFA Reauthorization

Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say system needs reform.

BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval

While it would not grab as much attention as creating a whole new approval pathway, BIO believes tinkering with accelerated approval to give the regulations more clarity and increase its use still could generate the change it wants at FDA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS073766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel